Amgen's experimental jab causes 20 per cent weight loss in early results
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
Wegovy is a weight-loss drug. Health Canada says it can now be used to curb heart-attack risk
Canada's health regulator has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
The Economist3h
Wegovy hits the People’s Republic, at last
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Pharmaceutical Technology6h
Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, to reduce the risk of non-fatal myocardial ...
healthday20h
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, includ ...
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
TCTMD23h
CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.